1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H2 2020, provides an overview of the Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline landscape.
Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 10, 2, 14, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Peripheral Arterial Disease Peripheral Vascular Disease - Overview
- Peripheral Arterial Disease Peripheral Vascular Disease - Therapeutics Development
- Peripheral Arterial Disease Peripheral Vascular Disease - Therapeutics Assessment
- Peripheral Arterial Disease Peripheral Vascular Disease - Companies Involved in Therapeutics Development
- Peripheral Arterial Disease Peripheral Vascular Disease - Drug Profiles
- Peripheral Arterial Disease Peripheral Vascular Disease - Dormant Projects
- Peripheral Arterial Disease Peripheral Vascular Disease - Discontinued Products
- Peripheral Arterial Disease Peripheral Vascular Disease - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Alucent Biomedical Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AptaBio Therapeutics Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ARCA biopharma Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ArtGen Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celularity Inc, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Constant Therapeutics LLC, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2020
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alucent Biomedical Inc
- AnGes Inc
- AptaBio Therapeutics Inc
- ARCA biopharma Inc
- ArtGen Inc
- Athera Biotechnologies AB
- Athersys Inc
- Bayer AG
- Betagenon AB
- BiogenCell Ltd
- Celularity Inc
- Constant Therapeutics LLC
- CuRAGE Therapeutics Inc
- Exodos Life Sciences Limited Partnership
- Foresee Pharmaceuticals Co Ltd
- Gurus BioPharm
- Helixmith Co Ltd
- Hemostemix Inc
- ID Pharma Co Ltd
- JanOne Inc
- Juventas Therapeutics Inc
- Laboratoris Sanifit SL
- LipimetiX Development Inc
- LTT Bio-Pharma Co Ltd
- MediaPharma SRL
- Nangiotx Inc
- Pharmosa Biopharm Inc
- Polysan NTFF Ltd
- Recardio GmbH
- Resverlogix Corp
- Reven Pharmaceuticals Inc
- Sorrento Therapeutics Inc
- Stemedica Cell Technologies Inc
- Symic Bio Inc
- Vascugen Inc
- Venturis Therapeutics Inc
- VESSL Therapeutics Ltd
- Zelira Therapeutics Ltd
- Zhittya Genesis Medicine Inc
